Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E.

Mol Cancer Res. 2019 Oct;17(10):2063-2076. doi: 10.1158/1541-7786.MCR-19-0040. Epub 2019 Jul 18.

PMID:
31320385
2.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
3.

How Anesthetic, Analgesic and Other Non-Surgical Techniques During Cancer Surgery Might Affect Postoperative Oncologic Outcomes: A Summary of Current State of Evidence.

Forget P, Aguirre JA, Bencic I, Borgeat A, Cama A, Condron C, Eintrei C, Eroles P, Gupta A, Hales TG, Ionescu D, Johnson M, Kabata P, Kirac I, Ma D, Mokini Z, Guerrero Orriach JL, Retsky M, Sandrucci S, Siekmann W, Štefančić L, Votta-Vellis G, Connolly C, Buggy D.

Cancers (Basel). 2019 Apr 28;11(5). pii: E592. doi: 10.3390/cancers11050592. Review.

4.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P.

Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y.

5.

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.

Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P.

Clin Epigenetics. 2019 Feb 20;11(1):33. doi: 10.1186/s13148-019-0626-0.

6.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

7.

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.

Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, González-Alonso P, Albanell J, Rovira A, Rojo F, Lluch A, Eroles P.

Sci Rep. 2017 Jan 25;7:41309. doi: 10.1038/srep41309.

8.

CIP2A confirms its prognostic value in triple-negative breast cancer.

Cristóbal I, Zazo S, Torrejón B, Pedregal M, Madoz-Gúrpide J, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Rojo F.

Oncogene. 2017 Jun 8;36(23):3357-3358. doi: 10.1038/onc.2016.474. Epub 2017 Jan 9. No abstract available.

PMID:
28068327
9.

Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

Gonzalez-Alonso P, Cristobal I, Zazo S, Martin-Aparicio E, Chamizo C, Madoz-Gurpide J, Rovira A, Eroles P, Lluch A, Albanell J, Rojo F.

Curr Med Chem. 2018;25(17):1976-1998. doi: 10.2174/0929867323666161216144659. Review.

PMID:
27993109
10.

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, Rojo F.

Am J Cancer Res. 2016 Nov 1;6(11):2661-2678. eCollection 2016.

11.

c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer.

Rincón R, Zazo S, Chamizo C, Manso R, González-Alonso P, Martín-Aparicio E, Cristóbal I, Cañadas C, Perona R, Lluch A, Eroles P, García-Foncillas J, Albanell J, Rovira A, Madoz-Gúrpide J, Rojo F.

Mol Cancer Ther. 2016 Nov;15(11):2780-2790. Epub 2016 Sep 6.

12.

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.

Cabello P, Pineda B, Tormo E, Lluch A, Eroles P.

Int J Mol Sci. 2016 Aug 10;17(8). pii: E1298. doi: 10.3390/ijms17081298.

13.

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.

Rojo F, González-Pérez A, Furriol J, Nicolau MJ, Ferrer J, Burgués O, Sabbaghi M, González-Navarrete I, Cristobal I, Serrano L, Zazo S, Madoz J, Servitja S, Tusquets I, Albanell J, Lluch A, Rovira A, Eroles P.

Br J Cancer. 2016 Jul 26;115(3):322-31. doi: 10.1038/bjc.2016.204. Epub 2016 Jul 12.

14.

BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.

Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC.

Leuk Res. 2015 Aug 28. pii: S0145-2126(15)30367-2. doi: 10.1016/j.leukres.2015.08.014. [Epub ahead of print]

PMID:
26344465
15.

MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.

Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, Chirivella E, Climent J, Lluch A, Eroles P.

J Cell Biochem. 2015 Sep;116(9):2061-73. doi: 10.1002/jcb.25162.

PMID:
25802200
16.

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.

Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Madoz-Gúrpide J, Rojo F.

Oncotarget. 2015 Feb 28;6(6):4299-314.

18.

Oxidative stress in susceptibility to breast cancer: study in Spanish population.

Rodrigues P, de Marco G, Furriol J, Mansego ML, Pineda-Alonso M, Gonzalez-Neira A, Martin-Escudero JC, Benitez J, Lluch A, Chaves FJ, Eroles P.

BMC Cancer. 2014 Nov 21;14:861. doi: 10.1186/1471-2407-14-861.

19.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
20.

MicroRNA profile in very young women with breast cancer.

Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G.

BMC Cancer. 2014 Jul 21;14:529. doi: 10.1186/1471-2407-14-529.

21.

Emerging EGFR antagonists for breast cancer.

Lluch A, Eroles P, Perez-Fidalgo JA.

Expert Opin Emerg Drugs. 2014 Jun;19(2):165-81. doi: 10.1517/14728214.2014.903919. Epub 2014 May 15. Review.

PMID:
24831079
22.

Concordance of genomic alterations between primary and recurrent breast cancer.

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM.

Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7.

23.

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.

Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F.

Oncotarget. 2014 Jan 15;5(1):196-210.

24.

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM.

Breast. 2013 Oct;22(5):974-9. doi: 10.1016/j.breast.2013.05.014. Epub 2013 Jun 25.

25.

Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P.

Mol Cell Biochem. 2013 Jul;379(1-2):181-90. doi: 10.1007/s11010-013-1640-8. Epub 2013 Apr 6.

PMID:
23716179
26.

Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.

Rodrigues P, Furriol J, Bermejo B, Chaves FJ, Lluch A, Eroles P.

Int J Mol Sci. 2012 Dec 5;13(12):16500-13. doi: 10.3390/ijms131216500.

27.

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

Pineda B, García-Pérez MÁ, Cano A, Lluch A, Eroles P.

PLoS One. 2013;8(1):e53902. doi: 10.1371/journal.pone.0053902. Epub 2013 Jan 16.

28.

The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P.

Breast Cancer Res Treat. 2012 Jun;133(2):769-78. doi: 10.1007/s10549-012-1980-1.

PMID:
22315135
29.

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A.

Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Review.

PMID:
22178455
30.

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.

Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J.

Ann Oncol. 2012 May;23(5):1156-64. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9.

PMID:
21908496
31.

Mechanisms of resistance to hormonal treatment in breast cancer.

Eroles P, Bosch A, Bermejo B, Lluch A.

Clin Transl Oncol. 2010 Apr;12(4):246-52. doi: 10.1007/s12094-010-0500-1. Review.

PMID:
20462833
32.

Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A.

Cancer Treat Rev. 2010 May;36(3):206-15. doi: 10.1016/j.ctrv.2009.12.002. Epub 2010 Jan 8. Review.

PMID:
20060649
33.

VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.

Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, Del Cerro MH, García-Marco JA, Terol MJ, García-Pardo A.

Blood. 2010 Jan 28;115(4):846-9. doi: 10.1182/blood-2009-08-239426. Epub 2009 Nov 19.

34.

Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation.

Zaragozá R, Torres L, García C, Eroles P, Corrales F, Bosch A, Lluch A, García-Trevijano ER, Viña JR.

Biochem J. 2009 Apr 15;419(2):279-88. doi: 10.1042/BJ20081746.

PMID:
19125694
35.

In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.

Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, Asgari Z, Hooper AT, La Perle KM, Hilsher C, Gao SJ, Dittmer DP, Rafii S, Mesri EA.

Cancer Cell. 2007 Mar;11(3):245-58. Erratum in: Cancer Cell. 2007 May;11(5):471.

36.

Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.

Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, Silverstein RL, Rafii S, Mesri EA.

Cancer Cell. 2003 Feb;3(2):131-43.

37.

Pharmacology of the receptors for the phorbol ester tumor promoters: multiple receptors with different biochemical properties.

Kazanietz MG, Caloca MJ, Eroles P, Fujii T, García-Bermejo ML, Reilly M, Wang H.

Biochem Pharmacol. 2000 Nov 15;60(10):1417-24.

PMID:
11020443
38.

The highly immunogenic enolase and Hsp70p are adventitious Candida albicans cell wall proteins.

Eroles P, Sentandreu M, Elorza MV, Sentandreu R.

Microbiology. 1997 Feb;143 ( Pt 2):313-20.

PMID:
9043108
39.

Cloning of a DNA fragment encoding part of a 70-kDa heat shock protein of Candida albicans.

Eroles P, Sentandreu M, Elorza MV, Sentandreu R.

FEMS Microbiol Lett. 1995 Apr 15;128(1):95-100.

PMID:
7744244

Supplemental Content

Loading ...
Support Center